Status:
UNKNOWN
Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients
Lead Sponsor:
Sun Yat-sen University
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Nasopharyngeal carcinoma (NPC) is one of the most common maligancies of China. In the era of intensity-modulated radiotherapy (IMRT), the 5-year overall survival (OS) has now reached 85.0% or more. Ho...
Detailed Description
Nasopharyngeal carcinoma (NPC) is one of the most common maligancies of China. In the era of intensity-modulated radiotherapy (IMRT), the 5-year overall survival (OS) has now reached 85.0% or more. Ho...
Eligibility Criteria
Inclusion
- Pathologic dianosis of nasopharyngeal carcinoma
- Stage of T1-4N2-3M0 (UICC/AJCC classification ver. 7)
- 18-70 years old
- Karnofsky performance score \> 70
Exclusion
- Distant metastasis before or during radiotherapy
- Severe dysfunctions of liver, kidney, lung, heart of bone marrow which are not fit for radiotherapy
- Prior malignancies
- Prior history of radiotherapy, chemotherapy or monoclonal antibody therapy
- Participation of other drug trials within 3 months
- Regular use of aspirin before dianosis
- Contraindication or allergy of aspirin
- Patients who are considered by the researchers not suitable to participate this trial
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2024
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT03290820
Start Date
January 1 2018
End Date
September 30 2024
Last Update
October 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060